The latest guidance to implement first-time drug price negotiation under Medicare said federal officials still are looking for a process [...] …
Month: July 2023
340B INDUSTRY LEADER SPOTLIGHT
Christopher Cooper, Health Systems Solutions Director, AllianceRx Walgreens Pharmacy
Q: Where did you grow up?
I was born and raised in Northwest Indiana and have lived in the Chicago area for the past 25 years.
Q: Where
…
U.S. Sen Bill Cassidy (La.), the top Republican on the Senate Health, Education, Labor, and Pensions Committee, said in an [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The national health center group promoting 340C—a proposed alternative to the 340B drug pricing program for health centers, federal grantees, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The Origin and Evolution of Specialty Pharmacy
Commencing in the early 1970s, specialty pharmacy was originally intended for patients requiring unique therapies for various conditions. Initially this included mainly infusions for hemophilia, cancer, or malnutrition[i]. Most of these offerings came with high costs (many of which can now be offset by copay assistance programs), and special storage and/or shipping requirements[ii].
Specialty pharmacy has since expanded rapidly, and Merck’s launch of indinavir (Crixivan®) in 1996 marked a significant milestone. As the third approved protease inhibitor for HIV treatment, the launch followed a record setting fast-track FDA approval. The decision to dispense Crixivan® exclusively through Stadtlanders specialty pharmacy[iii] set the tone for the limited distribution networks that we see today.
Between 1970 and 2000, most specialty medications were covered as a medical expense. However, a shift occurred in the early 2000s, with specialty transitioning to the pharmacy benefit. Today,
…
The National Rural Health Association has intensified its 340B advocacy work with a new congressional campaign and set of policy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
340B Report, the indispensable source for news and intelligence on the 340B drug pricing program, has added two team members with deep health care journalism experience. Rich Daly, a veteran healthcare business and policy journalist, is 340B Report’s new editor
…
Drug manufacturers Astellas and AstraZeneca announced today separate contract pharmacy policies for 340B providers that will go into effect in [...] …